Irish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

The Role of Pyroptosis in Chronic Venous Disease

Ní féidir ach le húsáideoirí cláraithe ailt a aistriú
Logáil Isteach / Cláraigh
Sábháiltear an nasc chuig an gearrthaisce
StádasGníomhach, ní ag earcú
Urraitheoirí
University of Catanzaro

Keywords

Coimriú

Enrollment criteria and clinical data collection: following the principles of medical ethics, the development of inclusion and exclusion criteria. Selecting 200 cases of chronic venous disease (CVD) according to the Comprehensive Classification System for Chronic Venous Disorders (CEAP) divided into 6 Clinical stages (C1-C6) (Group A). Selecting 200 healthy participants without CVD (C0) as controls (Group B). Blood samples will be collected from both groups. Markers of pyroptosis (NETs, Caspase-1 and Cytokines) will be evaluated between the two groups and between the subgroups, according to clinical stage, in group A.

Cur síos

Pyroptosis is a pro-inflammatory form of regulated cell death and is dependent on networks of extracellular fibers (NET,s), on the enzymatic activity of inflammatory proteases that belong to the family of cysteine-dependent aspartate-specific proteases (caspase), and cytokines. The role of inflammation has been previously demonstrated in chronic venous disease (CVD), which is a condition that affects up to 80% of adult population in western countries.

According to the Comprehensive Classification System for Chronic Venous Disorders (CEAP) divided into 6 Clinical stages:

C0: no visible or palpable signs of venous disease. C1: telangiectasies or reticular veins. C2: varicose veins. C3: edema. C4a: pigmentation and eczema. C4b: lipodermatosclerosis and atrophie blanche. C5: healed venous ulcer. C6: active venous ulcer.

The aim of this study is to evaluate the role of pyroptosis in the onset and progression of CVD.

The Investigators will select 200 participants with chronic venous disease (CVD) according to Clinical stage of CEAP (C1-C6 patients) [Group A] . The investigators will also select 200 healthy participants without CVD (C0) as controls [Group B].

Peripheral vein blood samples will be collected from both groups. Markers of pyroptosis (NETs, Caspase-1 and Cytokines) will be evaluated between the two groups and between the subgroups of group A, according to clinical stage.

Dátaí

Fíoraithe Deireanach: 10/31/2018
Cuireadh isteach den chéad uair: 11/11/2018
Clárú Measta Curtha isteach: 11/14/2018
Arna chur suas ar dtús: 11/15/2018
Nuashonrú Deireanach Curtha isteach: 11/14/2018
Nuashonrú Deireanach Postáilte: 11/15/2018
Dáta Tosaigh an Staidéir Iarbhír: 11/11/2018
Dáta Críochnaithe Bunscoile Measta: 11/11/2019
Dáta Críochnaithe an Staid Mheasta: 11/11/2020

Coinníoll nó galar

Inflammation
Veins
Complication
Varicose Veins
Varicose Ulcer

Idirghabháil / cóireáil

Procedure: Peripheral blood draw

Céim

-

Grúpaí Láimhe

LámhIdirghabháil / cóireáil
Group A - Participants with CVD
Patients with chronic venous disease (CVD) will undergo peripheral blood draw. Markers of pyroptosis (NETs, Caspase-1 and Cytokines) will be evaluated in blood samples.
Group B - Healthy Participants
Voluntary healthy subjects will undergo peripheral blood draw. Markers of pyroptosis (NETs, Caspase-1 and Cytokines) will be evaluated in blood samples.

Critéir Incháilitheachta

Aois Incháilithe le haghaidh Staidéir 18 Years Chun 18 Years
Gnéas Incháilithe le haghaidh StaidéirAll
Modh samplálaNon-Probability Sample
Glacann Oibrithe Deonacha SláintiúlaSea
Critéir

Inclusion Criteria:

- Chronic Venous Disease (C1-C6 CEAP classification )

Exclusion Criteria:

- Peripheral artery disease

- Malignant Tumors

- Severe cardiovascular and cerebrovascular disease

- Liver and kidney failure

Toradh

Bearta Toraidh Príomhúla

1. Pyroptosis evaluation 1 [2 years]

NETs evaluation to be presented in ng/ml

2. Pyroptosis evaluation 2 [2 years]

Caspase-1 evaluation to be presented in pg/ml

3. Pyroptosis evaluation 3 [2 years]

IL-1 β, IL-4, IL-10, IL-18, and TNF-α evaluation to presented in pg/ml

Bí ar ár
leathanach facebook

An bunachar luibheanna míochaine is iomláine le tacaíocht ón eolaíocht

  • Oibreacha i 55 teanga
  • Leigheasanna luibhe le tacaíocht ón eolaíocht
  • Aitheantas luibheanna de réir íomhá
  • Léarscáil GPS idirghníomhach - clibeáil luibheanna ar an láthair (ag teacht go luath)
  • Léigh foilseacháin eolaíochta a bhaineann le do chuardach
  • Cuardaigh luibheanna míochaine de réir a n-éifeachtaí
  • Eagraigh do chuid spéiseanna agus fanacht suas chun dáta leis an taighde nuachta, trialacha cliniciúla agus paitinní

Clóscríobh symptom nó galar agus léigh faoi luibheanna a d’fhéadfadh cabhrú, luibh a chlóscríobh agus galair agus comharthaí a úsáidtear ina choinne a fheiceáil.
* Tá an fhaisnéis uile bunaithe ar thaighde eolaíoch foilsithe

Google Play badgeApp Store badge